rentiated, proprietary NSA drug candidates, which includes over 350 filed patents with more than 100 already granted. We are approaching the commercialization of HLP003 with strong clinical data and significant market potential, subject to the receipt of all necessary approvals. Our new identity represents who we are today and where we expect to be tomorrow—an innovative company focused on redefining mental health care with the goal of helping minds heal.”

The evolution of the Company reflects its ongoing transformation as a global clinical stage discovery and development company to a commercial pharmaceutical company poised to deliver NSAs as groundbreaking therapies through rigorous patient-centered research and clinical excellence. These proprietary NSAs are purposefully designed to unlock healing of the mind and allow individuals to achieve durable recovery.

The Company has transferred its U.S. stock exchange listing from the NYSE American (p
=*=*=*=*=*=
当前为第3/11页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页